Complete financial analysis of PainReform Ltd. (PRFX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PainReform Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Targa Exploration Corp. (TEX.CN) Income Statement Analysis – Financial Results
- The Scottish Oriental Smaller Companies Trust plc (SST.L) Income Statement Analysis – Financial Results
- Cryptology Asset Group plc (CAGPF) Income Statement Analysis – Financial Results
- NEXON Co., Ltd. (3659.T) Income Statement Analysis – Financial Results
- Starry Group Holdings, Inc. (STRYQ) Income Statement Analysis – Financial Results
PainReform Ltd. (PRFX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.painreform.com
About PainReform Ltd.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 15.00K | 7.00K | 0.00 | 1.00K | 0.00 | 0.00 |
| Gross Profit | -15.00K | 71.00K | -7.00K | 0.00 | -1.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 82.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.04M | 4.42M | 2.86M | 354.00K | 136.00K | 223.00K | 504.00K |
| General & Administrative | 3.48M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Selling & Marketing | 66.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.55M | 4.45M | 4.35M | 1.32M | 553.00K | 277.00K | 376.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Cost & Expenses | 9.58M | 8.87M | 7.21M | 1.67M | 689.00K | 500.00K | 877.00K |
| Interest Income | 406.00K | 160.00K | 0.00 | 1.05K | 588.00 | 0.00 | 245.00K |
| Interest Expense | 384.00K | 61.00K | 10.00K | 987.00K | 541.00K | 324.00K | 0.00 |
| Depreciation & Amortization | 15.00K | 15.00K | 7.00K | 1.00K | 1.00K | 500.00K | 880.00K |
| EBITDA | -9.57M | -8.85M | -7.20M | -1.67M | -688.00K | 0.00 | -1.21M |
| EBITDA Ratio | 0.00% | -10,124.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.58M | -8.87M | -7.21M | -1.67M | -689.00K | -500.00K | -880.00K |
| Operating Income Ratio | 0.00% | -10,312.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 248.00K | 86.00K | -32.00K | -2.16M | -590.00K | -328.00K | -242.00K |
| Income Before Tax | -9.34M | -8.78M | -7.24M | -3.83M | -1.28M | -828.00K | -1.12M |
| Income Before Tax Ratio | 0.00% | -10,212.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 8.00K | 9.00K | 6.00K | 220.00K | 541.00K | 4.00K | -242.00K |
| Net Income | -9.34M | -8.79M | -7.25M | -4.05M | -1.82M | -828.00K | -2.09M |
| Net Income Ratio | 0.00% | -10,223.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -42.86 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.67 |
| EPS Diluted | -42.83 | -8.25 | -7.38 | -3.46 | -1.96 | -1.43 | -36.25 |
| Weighted Avg Shares Out | 218.00K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.00K |
| Weighted Avg Shares Out (Dil) | 218.15K | 1.07M | 981.22K | 1.17M | 930.79K | 579.55K | 57.66K |
PainReform Announces Closing of $4 Million Public Offering
TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an...
PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from new studies demonstrating the superior in-vitro...
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has reached the 50% enrollment target for the...
PainReform Provides Year-End Business Update
Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy
PainReform to Present at the Microcap Conference in Atlantic City
TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap...
PainReform to Present at the Microcap Conference in Atlantic City
Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference...
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief
PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agreement for the...
PainReform Provides Business Update for the Third Quarter of 2023
Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd.
Source: https://incomestatements.info
Category: Stock Reports